Forte Biosciences (FBRX) Share-based Compensation (2016 - 2026)
Forte Biosciences (FBRX) reported Share-based Compensation of $3.2 million for Q1 2026, up 96.11% year-over-year from $1.6 million in Q1 2025, and up 90.93% quarter-over-quarter from $1.7 million in Q4 2025.
Forte Biosciences (FBRX) Share-based Compensation (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Share-based Compensation data on file, last reported at $3.2 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $3.2 million, up 96.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.8 million (up 99.87% YoY), and the FY2025 annual result was $6.3 million, up 102.2% from the prior year.
- Share-based Compensation grew to $3.2 million in Q1 2026 per FBRX's latest filing, from $1.7 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $3.2 million in Q1 2026 and troughed at $697000.0 in Q4 2024.
- A 5-year average of $1.2 million and a median of $877000.0 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation plunged 38.49% in 2022, then jumped 138.74% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $860000.0 in 2022, then fell by 9.3% to $780000.0 in 2023, then decreased by 10.64% to $697000.0 in 2024, then surged by 138.74% to $1.7 million in 2025, then soared by 90.93% to $3.2 million in 2026.
- Business Quant data shows FBRX's Share-based Compensation at $3.2 million in Q1 2026, $1.7 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | 3.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.18 Mn |
| Mar 31, 2026 | 3.18 Mn |
| Dec 31, 2025 | 1.66 Mn |
| Dec 31, 2025 | 1.66 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | 697,000.00 |
| Dec 31, 2024 | 697,000.00 |
| Sep 30, 2024 | 791,000.00 |
| Sep 30, 2024 | 791,000.00 |
| Jun 30, 2024 | 802,000.00 |
| Jun 30, 2024 | 802,000.00 |
| Mar 31, 2024 | 805,000.00 |
| Mar 31, 2024 | 805,000.00 |
| Dec 31, 2023 | 780,000.00 |
| Dec 31, 2023 | 780,000.00 |